Gilead Sciences, Inc.
GILD
(NASDAQ Global Select)

Recent

price

89.84

P/E

ratio

109.56

div

yld

3.43%

ROIC.AI

Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.
Similar Companies
Business
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Company News

  • Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics

  • Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

  • Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline

  • Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why

  • 3 Absurdly Cheap Stocks That Pay High Dividends

  • Why Gilead Sciences (GILD) Dipped More Than Broader Market Today

  • Calls of the Day: Gilead, Berkshire Hathaway and SLB

  • Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

  • Gilead voluntarily withdraws urothelial cancer drug in US

  • Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

  • This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

  • Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

  • Gilead's HIV Prevention Treatment Lenacapavir Shows Potential

  • Hunting For Magnificent Growth Next Year? Check Out These 7 Stocks.

  • Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

  • Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know

  • Consider Buying Gilead To Benefit From Its Strong Outlook, Favorable Valuation

  • GILD Grants Right for HIV PrEP Candidate to Six Generic Companies

  • Gilead to donate remdesivir for emergency use against Marburg disease in Rwanda

  • Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know